Compounds > tetraethylammonium
Page last updated: 2024-11-05

tetraethylammonium and Atherosclerotic Parkinsonism

tetraethylammonium has been researched along with Atherosclerotic Parkinsonism in 2 studies

Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haghdoost-Yazdi, H2
Piri, H1
Najafipour, R1
Faraji, A2
Fraidouni, N2
Dargahi, T1
Alipour Heidari, M1
Movahedi, M1
Hadibeygi, E1
Vaezi, F1

Other Studies

2 other studies available for tetraethylammonium and Atherosclerotic Parkinsonism

ArticleYear
Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model.
    Neurosciences (Riyadh, Saudi Arabia), 2017, Volume: 22, Issue:1

    Topics: 4-Aminopyridine; Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug

2017
Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
    Behavioural brain research, 2011, Sep-30, Volume: 223, Issue:1

    Topics: 4-Aminopyridine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Drug Interactions;

2011